Novel Coronavirus Disease 2019 (COVID-19)
SARS-CoV-2

mAbs Therapies for COVID-19 Update: As of 7/30/2021, REGEN-COV has an added indication for emergency use as post-exposure prophylaxis against COVID-19 in adults and pediatric individuals who are at high risk for progression to severe COVID-19, including hospitalization or death. Learn more here.

As of 6/25/2021 bamlanivimab and etesevimab (Eli Lilly) is no longer recommended for use due to low reactivity against COVID-19 variants of concern. Learn more here.


Last Updated 8/3/21

Treatments to prevent severe COVID-19

Several treatments are available to treat patients who are already diagnosed with COVID-19. Also known as COVID-19 therapeutics, these treatments commonly fall under three categories: Monoclonal antibodies (mAbs), antivirals, and convalescent plasma.  

Treatment before severe illness is critical in preventing hospitalization from COVID-19.  Learn how antibody treatments within the first 10 days of symptoms can help prevent severe outcomes from COVID-19:


What are COVID-19 Therapeutics?

COVID-19 therapeutics are treatments for patients who test positive for COVID-19 and may prevent COVID-19 transmission among adults and pediatric individuals who have been exposed to COVID-19. There are several categories of COVID-19 therapeutics currently available to treat patients. Among them: 


Key Resources For COVID-19 Therapeutics 

To keep up-to-date with the latest information on patient eligibility and treatment guidelines, visit the NIH’s guide for COVID-19 Treatment Guidelines

Additional Resources

For Patients
  • www.combatcovid.hhs.gov – How mAbs work, patient eligibility, and where to sign up, what you can expect when getting treatment.  
  • Cost of mAbs – mAbs for COVID-19 are available at no cost to patients on Medicare, regardless of immigration status. Healthcare facilities may ask for insurance details to bill your insurance company for administering the treatment if you have Medicaid or private insurance.
For Providers

Antibody Products

Antibody products used to treat COVID-19 include: 

  • Monoclonal antibodies (mAbs) 
  • COVID-19 Convalescent Plasma
  • Anti-SARS-CoV-2 Specific Immunoglobulin

Of the antibody types listed above, mAbs are the only therapeutic type currently recommended by the COVID-19 Treatment Panel of the National Institutes of Health to treat outpatients with mild to moderate COVID-19 who are at high risk for severe outcomes. Treatment of non-hospitalized patients with COVID-19 convalescent plasma or SARS-CoV-2 Specific immunoglobulins is not yet recommended. Learn more here.  

Monoclonal Antibodies (mAbs)

mAbs for COVID-19 are designed to block viral attachment and entry of the virus that causes COVID-19, thus neutralizing the virus. Patients who have been exposed to or may have COVID-19 and are not yet hospitalized may be eligible for treatment.

Patients must have a prescription from a healthcare provider in order to receive treatment. Learn more about mAbs for treating COVID-19 at the links below.

As of June 25, 2021, there are two mAb therapies available through FDA Emergency Use Authorization (EUA)

  • casirivimab plus imdevimab (Regeneron)
  • Sotrovimab (GlaxoSmithKline)
  • bamlanivimab plus etesevimab (Eli Lilly)– No longer distributed as of June 25, 2021 

In Phase 3 clinical trials, treatment of COVID-19 with mAbs was shown to reduce the relative risk of hospitalizations or death by more than 70% in newly diagnosed COVID-19 patients who were not hospitalized.
Source: Clinical Trials Arena

Convalescent Plasma for Hospitalized Patients

COVID-19 convalescent plasma is human plasma collected from individuals whose plasma contains anti-SARS-CoV-2 antibodies and meets donor eligibility requirements. Hospitalized patients with COVID-19 may improve faster if they receive plasma from those who have recovered from COVID-19 early in the course of disease, because it may have the ability to fight the virus that causes COVID-19.

  • On August 23, 2020, the FDA issued an EUA for COVID-19 convalescent plasma for the treatment of hospitalized patients with COVID-19. This treatment is only available to be administered in a hospital setting or clinical trial.
  • For information on clinical trials that are testing the use of COVID-19 convalescent plasma for COVID-19, please see www.clinicaltrials.gov.
Anti-SARS-CoV-2 Specific Immunoglobulin

There are currently no clinical data on the use of immunoglobulins in treating patients. Trials are in development but not yet enrolling participants. 


Antiviral Products

Antiviral therapeutics works to inhibit the replication of viruses in our bodies by stopping messenger RNA from relaying instructions to keep producing the genetic material needed for a virus to survive. As of June 25,2021, the only FDA-approved antiviral drug for the treatment of COVID-19 is Remdesivir.  

Remdesivir Antibody Therapeutic (Commercially known as Veklury)
  • Remdesivir is an antiviral drug that was approved by the FDA on October 22, 2020 for the treatment of COVID-19. This treatment is only available to be administered in a hospital setting through an intravenous infusion. 
  • More patient information can be found in the FDA Fact sheets here.
  • For more information, visit the FDA’s frequently asked questions page for remdesivir here, or visit Gilead’s resource center for healthcare providers.

On April 16, 2021, the FDA revoked the emergency use authorization (EUA) for bamlanivimab monotherapy. The current EUA for combination therapy with bamlanivimab with etesevimab remains active except in areas known to have higher circulation of the P1 variant (identified in Brazil).